Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(16):1201-1202; doi:10.1093/jnci/96.16.1201
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Webb, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Webb, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Under-Dosing Study Raises Questions About Ways to Improve Regimen Adherence

Tracy Webb

The first 10% of the full text of this article appears below.

The decision to modify a patient's chemotherapy regimen is one that is frequently made in the clinic, often because of toxicity experienced by the patient. But a study published late last year unveiled the extent to which courses of cancer drugs are altered: More than half of patients studied who were receiving adjuvant chemotherapy for breast cancer received less than 85% of the recommended dose of chemotherapy. One-quarter of these patients had delays between cycles; the rest received a reduced dose of the drugs.

"We [in the community] assumed everything appropriate was being done for our . . . [Full Text of this Article]

Neutropenia

High Costs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?